A Phase 3 interventional study of Meropenem and Pralurbactam and Ceftazidime-avibactam in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-17.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pneumonia, Bacterial with a site in China — 6 open to participants now, 6 under way, 2 of them phase 3. Pneumonia, Bacterial · China.
Among the 10 studies in Pneumonia, Bacterial with a site in China, this one is one of 3 that started in 2026, is one of 5 in phase 3, and was the 8th registered.
153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.
Browse Pneumonia, Bacterial studies →6 of the 10 studies in Pneumonia, Bacterial with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 18+
Zai Lab (Hong Kong), Ltd. · Sites in China
Ages 18+
Fujian Medical University Union Hospital · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.
Median enrollment 123 across the 8 interventional studies, 82 across the 2 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 9 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 1 study filed under Pneumonia, Bacterial — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumonia, Bacterial with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07512596Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria | 2027-07 |
| NCT07759934Jiangsu Aosaikang Pharmaceutical Co., Ltd.ASK0912 Versus Polymyxin B for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia | 2027-10-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Pneumonia, Bacterial with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Male or female participants ≥18 and ≤80 years of age
2. have a diagnosis of HAP/VAP.
3. have systemic signs and respiratory signs or symptoms of HAP/VAP.
4. New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening.
5. The estimated survival time is at lest 28 days.
Exclusion Criteria:
1. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia.
2. The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours.
3. Acute Physiology and Chronic Health Evaluation (APACHE) II score >30.
4. Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials.
5. Those who have a history of drug abuse or drug abuse within 6 months before screening.
6. Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices.
Drug: Meropenem and Pralurbactam
Drug: Ceftazidime-avibactam
Drug pages: Meropenem · Pralurbactam
3g,q8h,120min infusion
2.5g,q8h,120min infusion
Proportion of Participants Who Died Due to Any Cause Description: Due to Day 14,Proportion of Participants Who Died Due to Any Cause in mITT
Time frame: Day 14
Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.
Of 15 phase 3 interventional studies under Pneumonia, Bacterial, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meropenem · Pralurbactam
Qilu Pharmaceutical Co., Ltd. →